Am J Psychiatry 154:1760-1762, December 1997
© 1997 American Psychiatric Association
Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine
Maurizio Fava, M.D.,
Rosemarie Mulroy, B.A.,
Jonathan Alpert, M.D., Ph.D.,
Andrew A. Nierenberg, M.D., and
Jerrold F. Rosenbaum, M.D.
OBJECTIVE: The rate of adverse events following discontinuation of treatment with extended-release venlafaxine was compared with the rate associated with discontinuation of placebo administration. METHOD: The subjects were 20 outpatients with major depressive disorder who had participated in a multicenter, double-blind, placebo-controlled study of the efficacy of the new extended-release formulation of venlafaxine. RESULTS: During the 3 days after discontinuation of treatment with the study drug, seven (78%) of the nine venlafaxine-treated subjects and two (22%) of the nine placebo-treated patients reported the emergence of adverse events, a statistically significant difference. CONCLUSIONS: These results suggest that clinicians discontinuing venlafaxine treatment should consider tapering the medication dose gradually. (Am J Psychiatry 1997; 154:1760–1762)
This article has been cited by other articles:
|
|
|
|
 
P. M. Haddad and I. M. Anderson
Recognising and managing antidepressant discontinuation symptoms
Advan. Psychiatr. Treat.,
November 1, 2007;
13(6):
447 - 457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted
Evid. Based Ment. Health,
May 1, 1998;
1(2):
36 - 36.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1997
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
